<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Previous studies from our laboratory indicated that selective cannabinoid CB(2) <z:chebi fb="4" ids="48705">agonists</z:chebi> were able to attenuate <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>/reperfusion (I/R) injury </plain></SENT>
<SENT sid="1" pm="."><plain>The goal of current study is to further test whether this attenuation involves cerebral microcirculatory function during I/R injury </plain></SENT>
<SENT sid="2" pm="."><plain>Middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> with reperfusion (MCAO/R) was performed in male mice </plain></SENT>
<SENT sid="3" pm="."><plain>A selective CB(2) <z:chebi fb="4" ids="48705">agonist</z:chebi> was administered at different dosages and different times </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">Cerebral infarction</z:e> volume, neurological function and cerebral microcirculatory function (leukocyte/endothelial interactions, cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule expression and blood-brain barrier disruption) were examined in vivo and in vitro </plain></SENT>
<SENT sid="5" pm="."><plain>CB(2) knockout mice were subjected to MCAO/R following same procedures </plain></SENT>
<SENT sid="6" pm="."><plain>Administration of the CB(2) <z:chebi fb="4" ids="48705">agonist</z:chebi> at middle dosage exerted optimal effects in reducing <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> and improving neurological function compared with other dosage groups and control group </plain></SENT>
<SENT sid="7" pm="."><plain>Treatment with the CB(2) <z:chebi fb="4" ids="48705">agonist</z:chebi> at the optimal dose was still effective when given 3 h after MCAO </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="C0022118" disease_type="Disease or Syndrome" abbrv="">Transient ischemia</z:e> significantly increased leukocyte/endothelial interactions, <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecules expression and blood-brain barrier disruption which were <z:hpo ids='HP_0000001'>all</z:hpo> attenuated by pre-treatment with a CB(2) <z:chebi fb="4" ids="48705">agonist</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>CB(2) knockout mice showed larger <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> and worse neurological function compared to wide type </plain></SENT>
<SENT sid="10" pm="."><plain>In conclusion, CB(2) activation contributed to protecting the brain through the attenuation of cerebral microcirculatory dysfunction during cerebral I/R injury </plain></SENT>
</text></document>